Stay up to date with the latest research, tips, and trends in fitness, nutrition, and weight management.
A new global analysis of two antenatal treatments that reduce the risk of cerebral palsy and respiratory complications in premature babies reveals significant international variation in implementation.
Gene-altering chemicals found in humpback dolphins and finless porpoises, raising alarm they may end up in human food chain
Timely vaccinations critical as whooping cough spreads
'In some countries where they’ve seen low rates of cesarean section, they’ve actually seen slightly higher cerebral palsy and adverse incident rates,' the Oireachtas health committee heard
The federal government is awarding up to $144 million in contracts to several universities and other research teams to study age-related illnesses and healthy longevity.
🌳 Deforestation decline in the Amazons continue. 🦟 Bacteria in mosquitoes reduced dengue cases by 70%. 🧮 AI helps mathematicians solve problems that have been unsolved for decades.
Data demonstrating superior selectivity, safety and pharmacokinetics of RGT-0474060 were presented at the 21st Annual Huntington’s Disease Therapeutics Conference (CHDI) being held this week in Palm Springs, CARgenta is now advancing RGT-0474060 in IND-enabling studies with a goal to enter clinical trials in 2027 WOBURN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that preclinical data from its new Huntington’s disease (HD) drug candidate targeting PMS1, RGT-0474060, were presented at the 21st Annual HD Therapeutics Conference being held this week in Palm Springs, CA. The data, generated in a model of Huntington’s disease (HD), demonstrate robust efficacy and well tolerated in vivo safety. The pharmacokinetics of RGT-0474060 track with reduction in PMS1 RNA and protein levels, and a dose-dependent suppression and inhibition of somatic CAG-repeat expansion associated with HD.
Study finds participants saw reduction in depressive symptoms as researchers welcome ‘promising’ results
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen’s 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA.
As people age, it becomes harder to know who is on track for healthy years ahead and who may be at higher risk for serious decline.